← Back to Search

Locomotor Training + Testosterone for Spinal Cord Injury

Phase 2
Recruiting
Led By Dana M Otzel, Phd
Research Sponsored by North Florida Foundation for Research and Education
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 month, 3 months, 6 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial will study the feasibility of using testosterone replacement therapy along with locomotor training to improve walking function in men with spinal cord injuries and low testosterone levels.

Who is the study for?
Men over 18 with low testosterone and spinal cord injury (SCI) causing walking difficulties are eligible. They must be medically stable, not seeking fertility, and willing to follow the treatment plan. Exclusions include major recent surgeries, other serious health conditions or cancers, certain cardiovascular issues, severe kidney disease, untreated sleep apnea, specific bone density scores below a threshold.
What is being tested?
The study tests whether combining testosterone replacement therapy (TRT) with locomotor training (treadmill and overground walking assistance) improves muscle size, bone density, and walking in men with SCI and low testosterone levels.
What are the potential side effects?
Potential side effects of TRT may include acne or oily skin, increased red blood cell count which can lead to complications like blood clots if too high; mood swings or aggression; possible increase in risk for heart-related events; enlargement of breasts; reduced sperm production.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 month, 3 months, 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month, 3 months, 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
change in 6 min walk test (6MWT)
change in distal femur bone mineral density
change in thigh muscle cross-sectional area
Secondary study objectives
change in 10m walk test (10mWT)
change in bone formation marker
change in bone resorption marker
+1 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: testosterone enanthateExperimental Treatment1 Intervention
Testosterone enanthate via i.m. injection (100 mg/week)
Group II: locomotor training, testosterone enanthateExperimental Treatment2 Interventions
Treadmill and overground walking training and testosterone enanthate via i.m. injection (100 mg/week)
Group III: non-interventional controlActive Control1 Intervention
Non-interventional control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Locomotor Training
2013
N/A
~110
Testosterone enanthate
FDA approved

Find a Location

Who is running the clinical trial?

North Florida Foundation for Research and EducationLead Sponsor
13 Previous Clinical Trials
838 Total Patients Enrolled
North Florida/South Georgia Veterans Health SystemOTHER
7 Previous Clinical Trials
1,964 Total Patients Enrolled
Brooks RehabilitationOTHER
15 Previous Clinical Trials
1,884 Total Patients Enrolled
University of FloridaOTHER
1,409 Previous Clinical Trials
767,532 Total Patients Enrolled
Joshua F Yarrow, PhDStudy DirectorNorth Florida/South Georgia Veterans Health System
Dana M Otzel, PhdPrincipal InvestigatorNorth Florida/South Georgia Veterans Health System

Media Library

Locomotor Training Clinical Trial Eligibility Overview. Trial Name: NCT04460872 — Phase 2
Low Testosterone Research Study Groups: testosterone enanthate, locomotor training, testosterone enanthate, non-interventional control
Low Testosterone Clinical Trial 2023: Locomotor Training Highlights & Side Effects. Trial Name: NCT04460872 — Phase 2
Locomotor Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT04460872 — Phase 2
~0 spots leftby Jan 2025